Holen Sie sich die Stockscreener-App
3.57
1.65%
-0.06
Schlusskurs vom Vortag:
$3.63
Offen:
$3.62
24-Stunden-Volumen:
12,953
Relative Volume:
0.19
Marktkapitalisierung:
$56.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-23.87M
KGV:
-0.1815
EPS:
-19.67
Netto-Cashflow:
$-47.63M
1W Leistung:
-0.56%
1M Leistung:
+10.87%
6M Leistung:
+27.05%
1J Leistung:
+4.08%
1-Tages-Spanne:
$3.50
$3.635
1-Wochen-Bereich:
$3.50
$3.70
52-Wochen-Spanne:
$2.30
$3.93
Polypid Ltd Stock (PYPD) Company Profile
Vergleichen Sie PYPD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PYPD
Polypid Ltd
|
3.54 | 60.38M | 0 | -23.87M | -47.63M | -19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.08 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
743.96 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.59 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
922.80 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
197.94 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Polypid Ltd Stock (PYPD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Eingeleitet | Roth Capital | Buy |
| 2025-06-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2021-09-14 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-07-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-24 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2020-08-10 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-07-21 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-07-21 | Eingeleitet | Barclays | Overweight |
| 2020-07-21 | Eingeleitet | Raymond James | Outperform |
Alle ansehen
Polypid Ltd Aktie (PYPD) Neueste Nachrichten
How analysts rate PolyPid Ltd. stock todayJuly 2025 Retail & Daily Oversold Bounce Ideas - newser.com
What makes PolyPid Ltd. stock attractive to growth fundsJuly 2025 Setups & Trade Opportunity Analysis Reports - newser.com
Top chart patterns to watch in PolyPid Ltd.Buy Signal & Free Weekly Chart Analysis and Trade Guides - newser.com
Published on: 2025-11-19 04:16:34 - newser.com
Will PolyPid Ltd. stock outperform growth indexesJuly 2025 Big Picture & AI Powered Buy/Sell Recommendations - newser.com
Will PolyPid Ltd. rebound enough to break evenInsider Selling & Intraday High Probability Alerts - newser.com
Why PolyPid Ltd. stock could benefit from AI revolutionMarket Movement Recap & Risk Controlled Swing Trade Alerts - newser.com
What analysts say about PolyPid Ltd stockLong-Term Growth Stocks & Start Small. End Wealthy. - earlytimes.in
Roth Capital Issues Optimistic Estimate for PolyPid Earnings - Defense World
Published on: 2025-11-16 12:50:26 - newser.com
Wall Street Zen Upgrades PolyPid (NASDAQ:PYPD) to Hold - Defense World
PolyPid Advances D-PLEX₁₀₀ Towards FDA Submission and Commercial Readiness - MSN
Using flow based indicators on PolyPid Ltd.July 2025 Summary & Proven Capital Preservation Methods - newser.com
Published on: 2025-11-13 18:14:47 - newser.com
Roth Capital Maintains PolyPid (PYPD) Buy Recommendation - Nasdaq
Is PolyPid Ltd. stock undervalued vs historical averagesJuly 2025 Short Interest & Expert Curated Trade Setup Alerts - newser.com
PolyPid (PYPD) Sees Price Target Cut by Roth Capital | PYPD Stoc - GuruFocus
PolyPid Ltd. (NASDAQ:PYPD) Q3 2025 Earnings Call Transcript - Insider Monkey
PolyPid price target lowered to $9 from $10 at Roth Capital - TipRanks
PolyPid Ltd. Advances Towards Key Milestones in 2025 - TipRanks
Published on: 2025-11-12 21:51:34 - newser.com
Leading vs lagging indicators on PolyPid Ltd. performanceOptions Play & Free Growth Oriented Trading Recommendations - newser.com
PolyPid Ltd. Earnings Call: Progress and Potential - TipRanks
PolyPid Ltd (PYPD) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial Challenges By GuruFocus - Investing.com Canada
Earnings call transcript: PolyPid Q3 2025 shows mixed results, stock dips - Investing.com Australia
Transcript : PolyPid Ltd., Q3 2025 Earnings Call, Nov 12, 2025 - MarketScreener
PolyPid Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
PolyPid : Investor Presentation (29305a) - MarketScreener
PolyPid Keeps Moving Forward Despite Quarterly Losses - Finimize
PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results - The Manila Times
PolyPid Ltd. Advances Regulatory Strategy with FDA Pre-NDA Meeting and U.S. Partnership Discussions Following Positive Phase 3 Trial Results - Quiver Quantitative
Biopharma firm PolyPid's Q3 net loss narrows to $7.5 mln - MarketScreener
PolyPid (NASDAQ: PYPD) completes IMOH GMP inspection; FDA pre‑NDA set, NDA in 2026 - Stock Titan
PolyPid receives Nasdaq’s non-compliance letter - MSN
Why PolyPid Ltd. stock could rally in 20252025 Market Sentiment & Free Real-Time Market Sentiment Alerts - newser.com
Finanzdaten der Polypid Ltd-Aktie (PYPD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.09%
1.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):